Raymond James lowered the firm’s price target on Fusion Pharmaceuticals to $12 from $13 and keeps an Outperform rating on the shares following a model update. The analyst believes Fusion remains “materially undervalued: relative to its peers in radiopharma and emphasizes the company is “on the cusp of materially augmenting its pipeline.” The firm sees catalysts for the company in Q4 and Q1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FUSN: